<?xml version="1.0" encoding="UTF-8"?>

<rss version="0.91">
<channel>
	<title>Drugs.com - New Drug Approvals</title>
	<link>https://www.drugs.com/newdrugs.html</link>
	<description>New drug approvals news from Drugs.com. Comprehensive and up-to-date drug news for both consumers and healthcare professionals.</description>
	<language>en</language>

	<item>
		<title>FDA Approves Rybelsus (semaglutide), the First Oral GLP-1 Analog Treatment for Adults with Type 2 Diabetes</title>
		<link>https://www.drugs.com/newdrugs/fda-approves-rybelsus-semaglutide-first-oral-glp-1-analog-adults-type-2-diabetes-5058.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=FDA+Approves+Rybelsus+%28semaglutide%29%2C+the+First+Oral+GLP-1+Analog+Treatment+for+Adults+with+Type+2+Diabetes</link>
		<description>PLAINSBORO, N.J., Sept. 20, 2019 /PRNewswire/ -- Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved Rybelsus (semaglutide) tablets 7 mg or 14 mg for adults with type 2 diabetes that along with diet and...</description>
		<pubDate>Fri, 20 Sep 2019 18:09:40 GMT</pubDate>
	</item>

	<item>
		<title>FDA Approves Erleada (apalutamide) for the Treatment of Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)</title>
		<link>https://www.drugs.com/newdrugs/fda-approves-erleada-apalutamide-patients-metastatic-castration-sensitive-prostate-cancer-mcspc-5057.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=FDA+Approves+Erleada+%28apalutamide%29+for+the+Treatment+of+Patients+with+Metastatic+Castration-Sensitive+Prostate+Cancer+%28mCSPC%29</link>
		<description>HORSHAM, Pa., Sept. 17, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson &amp;amp; Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved Erleada (apalutamide) for the treatment of patients with...</description>
		<pubDate>Tue, 17 Sep 2019 05:09:48 GMT</pubDate>
	</item>

	<item>
		<title>FDA Approves Keytruda (pembrolizumab) plus Lenvima (lenvatinib) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma</title>
		<link>https://www.drugs.com/newdrugs/fda-approves-keytruda-pembrolizumab-plus-lenvima-lenvatinib-combination-patients-certain-types-5056.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=FDA+Approves+Keytruda+%28pembrolizumab%29+plus+Lenvima+%28lenvatinib%29+Combination+Treatment+for+Patients+with+Certain+Types+of+Endometrial+Carcinoma</link>
		<description>KENILWORTH, N.J., &amp;amp; WOODCLIFF LAKE, N.J.-- September 17, 2019 -- (BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the U.S. Food and Drug Administration (FDA) approved the...</description>
		<pubDate>Tue, 17 Sep 2019 02:09:19 GMT</pubDate>
	</item>

	<item>
		<title>FDA Approves Ibsrela (tenapanor) for the Treatment of Irritable Bowel Syndrome with Constipation</title>
		<link>https://www.drugs.com/newdrugs/fda-approves-ibsrela-tenapanor-irritable-bowel-syndrome-constipation-5052.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=FDA+Approves+Ibsrela+%28tenapanor%29+for+the+Treatment+of+Irritable+Bowel+Syndrome+with+Constipation</link>
		<description>FREMONT, Calif., Sept. 12, 2019 /PRNewswire/ -- Ardelyx, Inc. today announced that the U.S. Food and Drug Administration has approved Ibsrela (tenapanor), a 50 mg, twice daily oral pill for the treatment of irritable bowel syndrome with constipation...</description>
		<pubDate>Thu, 12 Sep 2019 21:09:38 GMT</pubDate>
	</item>

	<item>
		<title>FDA Approves Nucala (mepolizumab) for Six to 11-Year-Old Children with Severe Eosinophilic Asthma</title>
		<link>https://www.drugs.com/newdrugs/fda-approves-nucala-mepolizumab-six-11-year-old-children-severe-eosinophilic-asthma-5054.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=FDA+Approves+Nucala+%28mepolizumab%29+for+Six+to+11-Year-Old+Children+with+Severe+Eosinophilic+Asthma</link>
		<description>London UK - 12 September 2019 --&amp;nbsp;GlaxoSmithKline today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for use in children as young as six years old who are living with severe eosinophilic asthma....</description>
		<pubDate>Thu, 12 Sep 2019 01:09:58 GMT</pubDate>
	</item>

	<item>
		<title>FDA Approves Gvoke (glucagon), the First Ready-to-use Stable Liquid Glucagon for Severe Hypoglycemia</title>
		<link>https://www.drugs.com/newdrugs/fda-approves-gvoke-glucagon-first-ready-stable-liquid-glucagon-severe-hypoglycemia-5049.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=FDA+Approves+Gvoke+%28glucagon%29%2C+the+First+Ready-to-use+Stable+Liquid+Glucagon+for+Severe+Hypoglycemia</link>
		<description>CHICAGO--(BUSINESS WIRE)--Sep. 10, 2019-- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations,...</description>
		<pubDate>Tue, 10 Sep 2019 22:09:52 GMT</pubDate>
	</item>

	<item>
		<title>FDA Approves Ofev (nintedanib) for Interstitial Lung Disease Associated with Systemic Sclerosis or Scleroderma (SSc-ILD)</title>
		<link>https://www.drugs.com/newdrugs/fda-approves-ofev-nintedanib-interstitial-lung-associated-systemic-sclerosis-scleroderma-ssc-ild-5045.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=FDA+Approves+Ofev+%28nintedanib%29+for+Interstitial+Lung+Disease+Associated+with+Systemic+Sclerosis+or+Scleroderma+%28SSc-ILD%29</link>
		<description>September 06, 2019 -- The U.S. Food and Drug Administration today approved Ofev (nintedanib) capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma,...</description>
		<pubDate>Fri, 06 Sep 2019 21:09:57 GMT</pubDate>
	</item>

	<item>
		<title>FDA Approves Juvéderm Voluma XC For Mid-Face Injection Via Cannula</title>
		<link>https://www.drugs.com/newdrugs/fda-approves-juv-derm-voluma-xc-mid-face-via-cannula-5044.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=FDA+Approves+Juv%C3%A9derm+Voluma+XC+For+Mid-Face+Injection+Via+Cannula</link>
		<description>DUBLIN, Sept. 3, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) announced today it received U.S. Food and Drug Administration (FDA) approval for the use of Juv&amp;eacute;derm Voluma XC, a hyaluronic acid gel dermal filler, with a TSK STERiGLIDE&amp;trade;...</description>
		<pubDate>Tue, 03 Sep 2019 22:09:28 GMT</pubDate>
	</item>

	<item>
		<title>FDA Approves Nourianz (istradefylline) as an Add-On Drug to Treat Off Episodes in Adults with Parkinson’s Disease</title>
		<link>https://www.drugs.com/newdrugs/fda-approves-nourianz-istradefylline-add-off-episodes-adults-parkinson-s-5039.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=FDA+Approves+Nourianz+%28istradefylline%29+as+an+Add-On+Drug+to+Treat+Off+Episodes+in+Adults+with+Parkinson%E2%80%99s+Disease</link>
		<description>TOKYO--(BUSINESS WIRE)-- August 28, 2019 -- Kyowa Kirin Co., Ltd., (Kyowa Kirin, TYO: 4151) announces today that the U.S. Food and Drug Administration (FDA) has granted approval for Nourianz (istradefylline) for use as adjunctive treatment to...</description>
		<pubDate>Wed, 28 Aug 2019 00:08:25 GMT</pubDate>
	</item>

	<item>
		<title>FDA Approves Myobloc (rimabotulinumtoxinB) Injection for Chronic Sialorrhea</title>
		<link>https://www.drugs.com/newdrugs/fda-approves-myobloc-rimabotulinumtoxinb-chronic-sialorrhea-5038.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=FDA+Approves+Myobloc+%28rimabotulinumtoxinB%29+Injection+for+Chronic+Sialorrhea</link>
		<description>LOUISVILLE, Ky., Aug. 26, 2019 /PRNewswire/ -- US WorldMeds, LLC announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application (sBLA) for Myobloc (rimabotulinumtoxinB) injection for the...</description>
		<pubDate>Mon, 26 Aug 2019 23:08:45 GMT</pubDate>
	</item>

	<item>
		<title>FDA Approves Taltz (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)</title>
		<link>https://www.drugs.com/newdrugs/fda-approves-taltz-ixekizumab-active-ankylosing-spondylitis-radiographic-axial-spondyloarthritis-5037.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=FDA+Approves+Taltz+%28ixekizumab%29+for+the+Treatment+of+Active+Ankylosing+Spondylitis+%28Radiographic+Axial+Spondyloarthritis%29</link>
		<description>INDIANAPOLIS, Aug. 26, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Taltz (ixekizumab) injection 80 mg/mL for the treatment of adults with active ankylosing...</description>
		<pubDate>Mon, 26 Aug 2019 21:08:48 GMT</pubDate>
	</item>

	<item>
		<title>FDA Approves Xenleta (lefamulin) to Treat Community-Acquired Bacterial Pneumonia (CABP)</title>
		<link>https://www.drugs.com/newdrugs/fda-approves-xenleta-lefamulin-community-acquired-bacterial-pneumonia-cabp-5035.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=FDA+Approves+Xenleta+%28lefamulin%29+to+Treat+Community-Acquired+Bacterial+Pneumonia+%28CABP%29</link>
		<description>DUBLIN, Ireland, Aug. 19, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today...</description>
		<pubDate>Mon, 19 Aug 2019 22:08:06 GMT</pubDate>
	</item>

	<item>
		<title>FDA Approves Rinvoq (upadacitinib), an Oral JAK Inhibitor for the Treatment of Moderate to Severe Rheumatoid Arthritis</title>
		<link>https://www.drugs.com/newdrugs/fda-approves-rinvoq-upadacitinib-oral-jak-inhibitor-moderate-severe-rheumatoid-arthritis-5033.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=FDA+Approves+Rinvoq+%28upadacitinib%29%2C+an+Oral+JAK+Inhibitor+for+the+Treatment+of+Moderate+to+Severe+Rheumatoid+Arthritis</link>
		<description>NORTH CHICAGO, Ill., Aug. 16, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib), a 15 mg, once-daily oral...</description>
		<pubDate>Fri, 16 Aug 2019 22:08:13 GMT</pubDate>
	</item>

	<item>
		<title>FDA Approves Inrebic (fedratinib) for the Treatment of Patients With Myelofibrosis</title>
		<link>https://www.drugs.com/newdrugs/fda-approves-inrebic-fedratinib-patients-myelofibrosis-5032.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=FDA+Approves+Inrebic+%28fedratinib%29+for+the+Treatment+of+Patients+With+Myelofibrosis</link>
		<description>SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved Inrebic (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or...</description>
		<pubDate>Fri, 16 Aug 2019 21:08:56 GMT</pubDate>
	</item>

	<item>
		<title>FDA Approves Wakix (pitolisant), a First-in-Class Medication for the Treatment of Excessive Daytime Sleepiness in Adult Patients with Narcolepsy</title>
		<link>https://www.drugs.com/newdrugs/fda-approves-wakix-pitolisant-first-class-excessive-daytime-sleepiness-adult-patients-narcolepsy-5030.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=FDA+Approves+Wakix+%28pitolisant%29%2C+a+First-in-Class+Medication+for+the+Treatment+of+Excessive+Daytime+Sleepiness+in+Adult+Patients+with+Narcolepsy</link>
		<description>PLYMOUTH MEETING, PA, August 15, 2019 &amp;mdash; Harmony Biosciences, LLC (Harmony) announced today that the U.S. Food and Drug Administration (FDA) approved Wakix (pitolisant) for the treatment of excessive daytime sleepiness (EDS) in adult patients...</description>
		<pubDate>Thu, 15 Aug 2019 21:08:45 GMT</pubDate>
	</item>

	<item>
		<title>FDA Approves Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors</title>
		<link>https://www.drugs.com/newdrugs/fda-approves-rozlytrek-entrectinib-ros1-positive-metastatic-non-small-cell-lung-cancer-ntrk-gene-5031.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=FDA+Approves+Rozlytrek+%28entrectinib%29+for+People+With+ROS1-Positive%2C+Metastatic+Non-Small+Cell+Lung+Cancer+and+NTRK+Gene+Fusion-Positive+Solid+Tumors</link>
		<description>South San Francisco, CA -- August 15, 2019 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Rozlytrek (entrectinib) for the treatment of adults with...</description>
		<pubDate>Thu, 15 Aug 2019 21:08:07 GMT</pubDate>
	</item>

	<item>
		<title>FDA Approves Pretomanid for Highly Drug-Resistant Forms of Tuberculosis</title>
		<link>https://www.drugs.com/newdrugs/fda-approves-pretomanid-highly-resistant-forms-tuberculosis-5029.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=FDA+Approves+Pretomanid+for+Highly+Drug-Resistant+Forms+of+Tuberculosis</link>
		<description>NEW YORK August 14, 2019 - Pretomanid, a novel compound developed by the non-profit organization TB Alliance, was approved by the U.S. Food &amp;amp; Drug Administration (FDA) today for treating some of the most drug-resistant forms of tuberculosis...</description>
		<pubDate>Wed, 14 Aug 2019 20:08:01 GMT</pubDate>
	</item>

	<item>
		<title>FDA Approves Eylea (aflibercept) Injection Prefilled Syringe	</title>
		<link>https://www.drugs.com/newdrugs/fda-approves-eylea-aflibercept-prefilled-syringe-5028.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=FDA+Approves+Eylea+%28aflibercept%29+Injection+Prefilled+Syringe%09</link>
		<description>TARRYTOWN, N.Y., Aug. 13, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Chemistry, Manufacturing and Controls (CMC) Prior-Approval Supplement...</description>
		<pubDate>Tue, 13 Aug 2019 01:08:34 GMT</pubDate>
	</item>

	<item>
		<title>Janssen Announces U.S. FDA Accelerated Approval for Sirturo (bedaquiline) as Part of Combination Therapy to Treat Adolescents with Pulmonary Multidrug-Resistant Tuberculosis</title>
		<link>https://www.drugs.com/newdrugs/janssen-announces-u-s-fda-accelerated-approval-sirturo-bedaquiline-part-combination-therapy-5042.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=Janssen+Announces+U.S.+FDA+Accelerated+Approval+for+Sirturo+%28bedaquiline%29+as+Part+of+Combination+Therapy+to+Treat+Adolescents+with+Pulmonary+Multidrug-Resistant+Tuberculosis</link>
		<description>TITUSVILLE, NJ, August 9, 2019 &amp;mdash; The Janssen Pharmaceutical Companies of Johnson &amp;amp; Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted approval for Sirturo (bedaquiline) tablets as part of combination...</description>
		<pubDate>Fri, 09 Aug 2019 03:08:13 GMT</pubDate>
	</item>

	<item>
		<title>FDA Approves Turalio (pexidartinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumors (TGCT) in Adults</title>
		<link>https://www.drugs.com/newdrugs/fda-approves-turalio-pexidartinib-symptomatic-tenosynovial-giant-cell-tumors-tgct-adults-5026.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=FDA+Approves+Turalio+%28pexidartinib%29+for+the+Treatment+of+Symptomatic+Tenosynovial+Giant+Cell+Tumors+%28TGCT%29+in+Adults</link>
		<description>Today, the U.S. Food and Drug Administration granted approval to Turalio (pexidartinib) capsules for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and...</description>
		<pubDate>Fri, 02 Aug 2019 22:08:46 GMT</pubDate>
	</item>
</channel>
</rss>